fluconazole has been researched along with Elevated ICP (Intracranial Pressure) in 18 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Excerpt | Relevance | Reference |
---|---|---|
" CsA was immediately stopped, and tacrolimus for prevention of graft-versus-host disease (GVHD) was started on day 2." | 7.71 | Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. ( Asaka, M; Chiba, K; Hashino, S; Izumiyama, K; Suzuki, S; Takahata, M, 2001) |
"The combined infection of Actinomyces odontolyticus sepsis and cryptococcal encephalitis is first reported in this case report, and combined antibiotics with 'penicillin, amphotericin, and fluconazole' are effective." | 5.41 | Cryptococcal meningoencephalitis with Actinomyces odontolyticus sepsis: a case report and literature review. ( Hong, Q; Hong, Z; Huang, Q, 2023) |
" CsA was immediately stopped, and tacrolimus for prevention of graft-versus-host disease (GVHD) was started on day 2." | 3.71 | Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus. ( Asaka, M; Chiba, K; Hashino, S; Izumiyama, K; Suzuki, S; Takahata, M, 2001) |
"Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains a major cause of HIV-related deaths worldwide." | 2.58 | Treatment for HIV-associated cryptococcal meningitis. ( Eshun-Wilson, I; Ford, N; Jarvis, JN; Li, T; Rouse, B; Shapiro, AE; Tenforde, MW, 2018) |
" The optimal dosing of AmB remains unclear." | 2.44 | Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. ( Dedicoat, M; Dlamini, S; Paul, N; Sloan, D, 2008) |
"Cryptococcal meningitis is a difficult disease to treat and requires biochemical and haematological monitoring to detect the common adverse effects of treatment." | 2.39 | The management of cryptococcal meningitis in Papua New Guinea. ( Seaton, RA, 1996) |
"Cryptococcal meningitis is a fungal infection that is most commonly thought of as an opportunistic infection affecting immunocompromised patients, classically patients with Human Immunodeficiency (HIV) infection." | 1.56 | Cryptococcal meningitis in an immunocompetent patient. ( Lacy, AJ; Murphy, LS; Shah, KS; Smith, AT, 2020) |
"Triple antifungal agents combined with VPS could effectively reduce ICP, had faster rate of clearance of C." | 1.56 | Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure. ( Deng, X; Gan, Q; Jiang, Y; Li, M; Liu, J; Peng, F; Wang, Y; Xu, X, 2020) |
"Cryptococcal meningitis is the most common life-threatening fungal infection and is associated with high mortality in children." | 1.36 | The role of an Ommaya reservoir in the management of children with cryptococcal meningitis. ( Gao, F; Jiang, PF; Shen, SX; Shui, QX; Xia, ZZ; Yu, HM; Zhou, BL, 2010) |
"Two patients with HIV/AIDS (CD4 counts of 8 and 81 cells/mm(3)) presented with altered mental status, visual changes, florid cryptococcal meningitis, and elevated ICP (>500 mm CSF) without evidence of hydrocephalus on computed tomography scan." | 1.33 | The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis. ( McGirt, MJ; Rigamonti, D; Williams, MA; Woodworth, GF, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (11.11) | 18.2507 |
2000's | 6 (33.33) | 29.6817 |
2010's | 7 (38.89) | 24.3611 |
2020's | 3 (16.67) | 2.80 |
Authors | Studies |
---|---|
Huang, Q | 1 |
Hong, Z | 1 |
Hong, Q | 1 |
Temfack, E | 1 |
Boyer-Chammard, T | 1 |
Lawrence, D | 1 |
Delliere, S | 1 |
Loyse, A | 1 |
Lanternier, F | 2 |
Alanio, A | 1 |
Lortholary, O | 2 |
Murphy, LS | 1 |
Lacy, AJ | 1 |
Smith, AT | 1 |
Shah, KS | 1 |
Li, M | 1 |
Liu, J | 1 |
Deng, X | 1 |
Gan, Q | 1 |
Wang, Y | 1 |
Xu, X | 1 |
Jiang, Y | 1 |
Peng, F | 1 |
Tenforde, MW | 1 |
Shapiro, AE | 1 |
Rouse, B | 1 |
Jarvis, JN | 1 |
Li, T | 1 |
Eshun-Wilson, I | 1 |
Ford, N | 1 |
Meda, J | 1 |
Kalluvya, S | 1 |
Downs, JA | 1 |
Chofle, AA | 1 |
Seni, J | 1 |
Kidenya, B | 1 |
Fitzgerald, DW | 1 |
Peck, RN | 1 |
Sloan, D | 1 |
Dlamini, S | 1 |
Paul, N | 1 |
Dedicoat, M | 1 |
Soares, BM | 1 |
Santos, DA | 1 |
Kohler, LM | 1 |
da Costa César, G | 1 |
de Carvalho, IR | 1 |
dos Anjos Martins, M | 1 |
Cisalpino, PS | 1 |
Guevara-Campos, J | 1 |
González-Guevara, L | 1 |
Urbéz-Cano, J | 1 |
Fermín, S | 1 |
Blanch, JJ | 1 |
Rodríguez, M | 1 |
Escribano, E | 1 |
Atienzar, M | 1 |
Jiang, PF | 1 |
Yu, HM | 1 |
Zhou, BL | 1 |
Gao, F | 1 |
Shen, SX | 1 |
Xia, ZZ | 1 |
Shui, QX | 1 |
Jackson, A | 1 |
van der Horst, C | 1 |
Lachhab, L | 1 |
Rasmouni, K | 1 |
Ait Ben Haddou, EH | 1 |
Maamar, M | 1 |
Seffar, M | 1 |
Regragui, W | 1 |
Benomar, A | 1 |
Yahyaoui, M | 1 |
Woodworth, GF | 1 |
McGirt, MJ | 1 |
Williams, MA | 1 |
Rigamonti, D | 1 |
Lecuit, M | 1 |
Roujeau, T | 1 |
Renier, D | 1 |
Bougnoux, ME | 1 |
Ferreira, RC | 1 |
Phan, G | 1 |
Bateman, JB | 1 |
Seaton, RA | 1 |
Takahata, M | 1 |
Hashino, S | 1 |
Izumiyama, K | 1 |
Chiba, K | 1 |
Suzuki, S | 1 |
Asaka, M | 1 |
6 reviews available for fluconazole and Elevated ICP (Intracranial Pressure)
Article | Year |
---|---|
Cryptococcal meningoencephalitis with Actinomyces odontolyticus sepsis: a case report and literature review.
Topics: Actinomyces; Actinomycosis; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Fluconazole; | 2023 |
New Insights Into Cryptococcus Spp. Biology and Cryptococcal Meningitis.
Topics: Amphotericin B; Antifungal Agents; Antiretroviral Therapy, Highly Active; Cryptococcus; Drug Therapy | 2019 |
Treatment for HIV-associated cryptococcal meningitis.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Developing Countries; Drug A | 2018 |
Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings.
Topics: Acetazolamide; Acute Disease; Adult; Amphotericin B; Antifungal Agents; Antihypertensive Agents; Dev | 2008 |
New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 2012 |
The management of cryptococcal meningitis in Papua New Guinea.
Topics: Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Cause of Death; Drug Combinations; Drug | 1996 |
12 other studies available for fluconazole and Elevated ICP (Intracranial Pressure)
Article | Year |
---|---|
Cryptococcal meningitis in an immunocompetent patient.
Topics: Adult; Amphotericin B; Antifungal Agents; Culture Techniques; Delayed Diagnosis; Fluconazole; Flucyt | 2020 |
Triple therapy combined with ventriculoperitoneal shunts can improve neurological function and shorten hospitalization time in non-HIV cryptococcal meningitis patients with increased intracranial pressure.
Topics: Adult; Amphotericin B; Antifungal Agents; Cryptococcus neoformans; Drug Therapy, Combination; Female | 2020 |
Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study.
Topics: Administration, Intravenous; Adult; Antifungal Agents; Disease Management; Female; Fluconazole; HIV | 2014 |
Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing.
Topics: Amphotericin B; Antifungal Agents; Child; Cryptococcus; Drug Resistance, Multiple, Fungal; Drug Syne | 2008 |
[Cryptococcus neoformans meningoencephalitis in immunocompetent schoolchildren].
Topics: Amphotericin B; Animals; Animals, Domestic; Antifungal Agents; Blindness; Cerebrospinal Fluid; Child | 2009 |
[Cryptococcal meningitis with a fatal outcome in an immunocompetent adult].
Topics: Amphotericin B; Antifungal Agents; Combined Modality Therapy; Drainage; Drug Therapy, Combination; F | 2010 |
The role of an Ommaya reservoir in the management of children with cryptococcal meningitis.
Topics: Amphotericin B; Antifungal Agents; Child; Cryptococcus neoformans; Drug Delivery Systems; Female; Fl | 2010 |
Cryptococcosis in an immunocompetent pregnant woman.
Topics: Adult; Amphotericin B; Antifungal Agents; Apgar Score; Brain; Cryptococcosis; Female; Fluconazole; H | 2013 |
The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Dr | 2005 |
Successful lumbarperitoneal derivation during refractory intracranial pressure due to cryptococcal meningitis, in an HIV-negative patient.
Topics: Adolescent; Antifungal Agents; Cryptococcus neoformans; Fluconazole; HIV Seronegativity; Humans; Imm | 2008 |
Favorable visual outcome in cryptococcal meningitis.
Topics: Acetazolamide; Adolescent; Anti-Inflammatory Agents; Antifungal Agents; Dexamethasone; Female; Fluco | 1997 |
Cyclosporin A-induced encephalopathy after allogeneic bone marrow transplantation with prevention of graft-versus-host disease by tacrolimus.
Topics: Adult; Anemia, Aplastic; Anticonvulsants; Blood-Brain Barrier; Bone Marrow Transplantation; Brain Di | 2001 |